CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score -1.39: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
964.09MUSDvs all stocks (USD)
Revenue (TTM)
71.64MUSDvs all stocks (USD)
Beta
0.3500xvs all stocks
52-Week Change
67.85%vs all stocks
Market Capitalization
964.09MUSDvs all stocks (USD)
Enterprise Value
407.54MUSDvs all stocks (USD)
Forward P/E
-4.21xvs Biotechnology peers
Price to Sales (TTM)
13.46xvs Biotechnology peers
Price to Book (MRQ)
8.94xvs Biotechnology peers
Enterprise to Revenue
5.69xvs Biotechnology peers
Enterprise to EBITDA
-1.29xvs Biotechnology peers
Gross Margin
98.57%vs Biotechnology peers
Operating Margin
-431.51%vs Biotechnology peers
Return on Assets (TTM)
-28.44%vs Biotechnology peers
Return on Equity (TTM)
-124.74%vs Biotechnology peers
Revenue (TTM)
71.64MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.8140USDUpdated Jul 19, 2026Quarterly Revenue Growth
29.50%vs Biotechnology peers
Gross Profit (TTM)
-189.04MUSDvs all stocks (USD)
EBITDA (TTM)
-316.60MUSDvs all stocks (USD)
Net Income (TTM)
-294.57MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
29.47%vs Biotechnology peers
Operating Cash Flow (TTM)
-77.98MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-129.83MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
67.48MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
57.00KUSDFY2025 · Dec 31, 2025Gross Profit
67.42MUSDFY2025 · Dec 31, 2025Operating Income
-303.63MUSDvs all stocks (USD)
Pre-tax Income
-278.37MUSDFY2025 · Dec 31, 2025Income Tax Expense
297.00KUSDFY2025 · Dec 31, 2025Net Income
-278.67MUSDFY2025 · Dec 31, 2025EBIT
-276.86MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-275.82MUSDFY2025 · Dec 31, 2025Research & Development
251.07MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
119.98MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
26.77MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.51MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.18USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.18USDFY2025 · Dec 31, 2025Basic Shares Outstanding
87.68MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
87.68MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-278.67MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-52.27MUSDFY2025 · Dec 31, 2025Free Cash Flow
-58.91MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
149.10MUSDFY2025 · Dec 31, 2025Interest Paid
998.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-278.67MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.03MUSDFY2025 · Dec 31, 2025Stock-based Compensation
37.11MUSDFY2025 · Dec 31, 2025Other Non-cash Items
515.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.74MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.50MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
189.98MUSDFY2025 · Dec 31, 2025Capital Expenditures
-6.64MUSDFY2025 · Dec 31, 2025Purchase of Investments
-761.59MUSDFY2025 · Dec 31, 2025Sale of Investments
755.13MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-13.10MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
88.76MSharesUpdated Jul 19, 2026Float Shares
70.42MSharesUpdated Jul 19, 2026Shares Short
15.09MSharesUpdated Jul 19, 2026Short Ratio
7.94daysvs all stocks
Short % of Shares Outstanding
17.45%vs all stocks
% Held by Insiders
1.43%vs all stocks
% Held by Institutions
96.86%vs all stocks
Total Cash (MRQ)
580.82MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.54USDUpdated Jul 19, 2026Total Debt (MRQ)
24.27MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2250xvs Biotechnology peers
Current Ratio (MRQ)
6.15xvs Biotechnology peers
Book Value per Share (MRQ)
1.22USDUpdated Jul 19, 2026Total Assets
738.36MUSDvs all stocks (USD)
Total Current Assets
708.66MUSDFY2025 · Dec 31, 2025Total Liabilities
564.23MUSDFY2025 · Dec 31, 2025Total Non-current Assets
29.70MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
447.25MUSDFY2025 · Dec 31, 2025Total Current Liabilities
116.97MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
149.10MUSDFY2025 · Dec 31, 2025Other Short-term Investments
518.14MUSDFY2025 · Dec 31, 2025Accounts Receivable
8.80MUSDFY2025 · Dec 31, 2025Inventory
413.00KUSDFY2025 · Dec 31, 2025Accounts Payable
5.02MUSDFY2025 · Dec 31, 2025Short-term Debt
1.28MUSDFY2025 · Dec 31, 2025Deferred Revenue
48.98MUSDFY2025 · Dec 31, 2025Long-term Debt
19.18MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.17MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.17BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
174.13MUSDvs all stocks (USD)
52-Week Low
5.45USDUpdated Jul 19, 202652-Week High
12.49USDUpdated Jul 19, 202652-Week Change
67.85%vs all stocks
Beta
0.3500xvs all stocks
50-Day MA
10.09USDUpdated Jul 19, 2026200-Day MA
9.63USDUpdated Jul 19, 2026Avg 10-Day Volume
1.59MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.78MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-3.35USDUpdated Jul 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.15Altman Z-Score: -1.39
Financial Health
Altman Z-Score -1.39: distress zoneCritical
Altman Z-Score: -1.39
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Hob Biotech Group Suzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Seegene, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Er-Kang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Annexon, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Eos Energy Enterprises Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC